Pediatric platelet aggregation function testing is a specialized laboratory examination that evaluates how effectively a child's platelets clump together in response to physiological agonists, playing a critical role in diagnosing inherited and acquired bleeding disorders. This testing is essential for identifying conditions such as Glanzmann thrombasthenia, Bernard-Soulier syndrome, and von Willebrand disease, as well as for monitoring antiplatelet therapy in children with Kawasaki disease or congenital heart disease. This article provides a comprehensive technical overview of clinical platelet aggregation testing in children, covering sample requirements, testing items, analytical methods, quality standards, and clinical applications.
Technical Overview
Platelet aggregation function testing is a cornerstone of hemostatic laboratory diagnostics that quantitatively assesses the ability of platelets to activate and form aggregates upon stimulation by specific agonists. In pediatric patients, this testing carries particular clinical significance because inherited platelet function disorders frequently manifest in early childhood as mucocutaneous bleeding, including recurrent epistaxis, easy bruising, prolonged bleeding after dental procedures, and menorrhagia in adolescent females. Because platelet count measurement alone cannot detect qualitative defects, functional testing is indispensable when a child presents with a suggestive bleeding history despite a normal platelet count.
Pediatric platelet aggregation testing presents unique analytical challenges that distinguish it from adult testing. Children have age-dependent platelet reactivity, with neonatal and infant platelets demonstrating physiological hyporesponsiveness to agonists such as ADP, epinephrine, and collagen due to immature signal transduction pathways and reduced granule content. Sample volume constraints are a persistent concern in pediatrics, requiring laboratories to adopt low-volume protocols or alternative methodologies such as impedance aggregometry and flow cytometry. Additionally, venipuncture difficulty and emotional stress in young patients can activate platelets prior to analysis, making pre-analytical standardization critical.
Laboratories performing these tests should align their procedures with recognized standards and guidelines, including the CLSI H58-A guideline on platelet function testing by aggregometry, recommendations from the International Society on Thrombosis and Haemostasis (ISTH) on platelet function testing, and quality management requirements under ISO 15189 for medical laboratories. In China, national standard GB/T 22576 defines general requirements for quality and competence of medical laboratories and applies to accredited clinical hemostasis laboratories performing platelet function assays.
Testing Samples
Citrated Whole Blood
Whole blood collected into 3.2% (0.109 mol/L) sodium citrate anticoagulant at a strict 9:1 blood-to-anticoagulant ratio is the primary sample for impedance aggregometry and platelet function analyzer testing. This sample type is particularly advantageous in pediatric practice because it requires minimal processing, avoids centrifugation-induced platelet activation, and reduces the total blood volume needed. The sample should be gently inverted several times to ensure complete mixing, maintained at room temperature (15–25°C), and analyzed within the validated stability window, typically 30 minutes to 4 hours after collection.
Platelet-Rich Plasma (PRP)
Platelet-rich plasma is prepared by centrifuging citrated whole blood at low speed (approximately 150–200 × g for 10–15 minutes) without braking, allowing the platelet-containing layer to be carefully harvested. PRP is the required sample for light transmission aggregometry, the reference method for platelet function assessment. The platelet count in PRP should ideally be adjusted to a standardized range of 200–300 × 10⁹/L using autologous platelet-poor plasma, although in pediatric settings with limited volume, testing at the native count with result annotation is an accepted compromise.
Platelet-Poor Plasma (PPP)
Platelet-poor plasma is obtained by further centrifuging the residual blood at approximately 1,500–2,000 × g for 10–15 minutes. PPP serves as the optical blank for light transmission aggregometry and is used to dilute PRP when platelet count adjustment is required. PPP should have a platelet count below 10 × 10⁹/L to ensure accurate baseline calibration.
Sample Collection Considerations in Children
- Venipuncture should be performed by experienced pediatric phlebotomists using butterfly needles of appropriate gauge to minimize shear-induced platelet activation and hemolysis.
- The first few drops of blood should be discarded or collected into a discard tube to eliminate tissue factor contamination from the puncture site.
- Difficult or prolonged draws should be documented, as traumatic collection may produce falsely reduced aggregation results.
- Medication history must be recorded, and non-steroidal anti-inflammatory drugs, antihistamines, and certain antibiotics should ideally be withheld for 7–10 days before testing when clinically feasible.
- Sample rejection criteria include clots, hemolysis, underfilled tubes, and delayed transport beyond the validated stability period.
Testing Items
A comprehensive pediatric platelet aggregation panel typically includes stimulation with a panel of agonists at established concentrations, each targeting distinct platelet activation pathways:
- ADP-induced aggregation (5–20 µM): evaluates the ADP receptor (P2Y12 and P2Y1) pathway; reduced response suggests secretion defects or P2Y12 inhibitor exposure.
- Epinephrine-induced aggregation (5–10 µM): assesses the alpha-adrenergic potentiation pathway; frequently diminished in childhood even in healthy individuals, requiring careful interpretation.
- Collagen-induced aggregation (1–2 µg/mL): tests glycoprotein VI and integrin α2β1 signaling along with the release reaction; abnormal results occur in secretion defects.
- Arachidonic acid-induced aggregation (0.5–1.0 mM): evaluates the cyclooxygenase-thromboxane A2 pathway; suppressed by aspirin and abnormal in defects of thromboxane synthesis.
- Ristocetin-induced platelet agglutination (0.5–1.5 mg/mL): assesses von Willebrand factor–GPIb interaction; absent at high concentration in Bernard-Soulier syndrome and reduced in von Willebrand disease.
- TRAP-induced aggregation (25–50 µM): evaluates PAR-1 thrombin receptor signaling, useful for confirming normal GPIIb/IIIa-mediated aggregation pathways.
Reported analytical parameters for each agonist typically include maximum aggregation percentage, aggregation slope, lag phase duration, and, where applicable, disaggregation percentage. Age-specific or method-specific reference intervals must be established or verified by the performing laboratory, since direct application of adult reference ranges to neonates and young children can lead to misdiagnosis.
Testing Methods
Light Transmission Aggregometry (LTA)
Light transmission aggregometry, originally described by Born, remains the reference method for platelet aggregation assessment. PRP is stirred in a cuvette at 37°C while an agonist is added, and the increase in light transmission as platelets aggregate is recorded photometrically. PPP serves as the 100% transmission blank. LTA provides high sensitivity for detecting severe platelet function disorders, including Glanzmann thrombasthenia, in which aggregation is absent with all agonists except ristocetin, and Bernard-Soulier syndrome, in which the reverse pattern is observed. Its limitations in pediatrics include the relatively large blood volume required and dependence on adequate platelet counts (generally above 100 × 10⁹/L).
Whole Blood Impedance Aggregometry
Impedance-based aggregometry measures the change in electrical impedance between metal electrodes as platelets adhere and aggregate onto their surface following agonist stimulation. Because testing is performed directly on whole blood without centrifugation, this method requires smaller volumes, offers faster turnaround, and better preserves physiological conditions, making it well suited to pediatric applications. It is widely used for monitoring antiplatelet drug response and for point-of-care assessment of platelet reactivity.
Platelet Function Analyzer Testing
Automated platelet function analyzers measure the closure time required for whole blood under high shear to occlude an aperture in a collagen-coated membrane, using cartridges coated with collagen/ADP or collagen/epinephrine. This method requires only a small sample volume and no sample processing, functioning as a rapid screening tool for global primary hemostasis abnormalities, including severe von Willebrand disease and significant platelet function defects. Normal results do not exclude milder defects, so abnormal or clinically discordant findings warrant confirmatory aggregometry.
Flow Cytometric Platelet Function Analysis
Flow cytometry enables multiparametric evaluation of platelet activation markers and receptor expression, including PAC-1 binding to activated GPIIb/IIIa, P-selectin (CD62P) expression, fibrinogen binding, and surface glycoprotein quantification of GPIb, GPIIb/IIIa, and GPIa. This method requires only microliter volumes of whole blood, permits diagnosis of specific receptor defects such as Glanzmann thrombasthenia and Bernard-Soulier syndrome at the molecular phenotype level, and is increasingly valuable in pediatric and neonatal testing.
Viscoelastic Hemostatic Assay with Platelet Mapping
Thromboelastography and rotational thromboelastometry provide global assessment of clot formation and strength. With specialized platelet mapping modules, these assays can quantify the contribution of platelet function and the inhibitory effect of antiplatelet agents. They are useful in perioperative and critical care settings, including pediatric cardiac surgery and extracorporeal membrane oxygenation management.
Quality Assurance
- Participation in external quality assessment programs and inter-laboratory comparisons for platelet function testing is strongly recommended.
- Internal quality control materials should be run according to established schedules, with documented acceptance criteria.
- Pre-analytical variables, including time from collection to analysis, storage temperature, and agonist preparation, must be strictly controlled and documented.
- Laboratory procedures should comply with ISO 15189 and applicable national standards such as GB/T 22576 for competence and quality management.
Applications
Clinical detection of platelet aggregation function in children supports a broad spectrum of diagnostic and therapeutic decision-making scenarios:
- Diagnosis of inherited platelet function disorders: Characteristic agonist profiles confirm Glanzmann thrombasthenia (absent aggregation with all agonists except ristocetin), Bernard-Soulier syndrome (absent ristocetin response correctable in von Willebrand disease), storage pool disease, and secretion defects.
- Evaluation of von Willebrand disease: Ristocetin-induced platelet agglutination is an integral component of the diagnostic workup and classification of von Willebrand disease in children with mucocutaneous bleeding.
- Investigation of unexplained bleeding: Children with a positive bleeding history, normal platelet count, normal coagulation screening, and normal von Willebrand factor studies require platelet function testing to exclude qualitative disorders.
- Monitoring antiplatelet therapy: Low-dose aspirin is widely used in Kawasaki disease and following certain cardiac procedures; aggregation testing verifies therapeutic suppression of the cyclooxygenase pathway and identifies aspirin hypo-responsiveness requiring clinical adjustment.
- Perioperative and procedural risk assessment: Pre-procedural evaluation of platelet function guides transfusion planning and timing of elective surgery in children with suspected primary hemostatic defects.
- Critical care and extracorporeal circulation: Platelet function testing assists in managing acquired platelet dysfunction associated with extracorporeal membrane oxygenation, cardiopulmonary bypass, sepsis, uremia, and disseminated intravascular coagulation.
- Neonatal hemostasis evaluation: Age-adjusted testing supports investigation of neonatal bleeding and differentiation between physiological hyporesponsiveness and pathological platelet dysfunction.
- Pharmacological and clinical research: Pediatric aggregation testing provides endpoints for studies of antithrombotic drugs, transfusion medicine, and developmental hemostasis.
FAQ
How much blood is required for pediatric platelet aggregation testing?
Sample requirements depend on the method. Light transmission aggregometry with a full agonist panel may require several milliliters of blood, while impedance aggregometry and platelet function analyzer testing typically need approximately 1–3 mL. Flow cytometry can be performed with less than 1 mL, making it advantageous for neonates and infants. Laboratories serving children should prioritize low-volume protocols and communicate minimum volume requirements clearly to clinical teams.
Should medications be stopped before testing?
Whenever clinically safe, drugs known to affect platelet function, including aspirin and other NSAIDs, should be withheld for at least 7–10 days prior to testing. Antihistamines, certain antibiotics, serotonin reuptake inhibitors, and some food supplements can also impair aggregation. If medication withdrawal is not feasible, results must be interpreted with the drug exposure documented, as pharmacological inhibition cannot be distinguished from intrinsic dysfunction without a washout period.
How are results interpreted differently in children compared with adults?
Neonatal and infant platelets are physiologically hyporesponsive to ADP, epinephrine, and collagen, and epinephrine responses may remain blunted throughout early childhood. Laboratories must apply age-appropriate reference intervals verified for their specific method and agonist concentrations. A result that appears abnormal against adult ranges may be normal for a young child, and vice versa, underscoring the importance of pediatric-specific interpretation.
What is the typical turnaround time?
Because platelet function declines over time after collection, testing is generally performed within 2–4 hours of venipuncture for light transmission aggregometry and within the method-specific validated window for whole blood assays. Preliminary results are often available the same day, with final interpretive reports issued within 24–72 hours once the full agonist panel and quality checks are complete.
What factors can interfere with test accuracy?
Common interference sources include traumatic venipuncture causing pre-activation, hemolysis, clotted or underfilled citrate tubes, delayed testing, storage at incorrect temperatures, thrombocytopenia below approximately 100 × 10⁹/L for PRP-based methods, severe anemia, and recent drug or dietary exposure affecting platelet reactivity. Adherence to standardized pre-analytical protocols is essential for reliable results.
Is fasting required before sample collection?
Fasting is not strictly required for platelet aggregation testing itself, but a high-fat meal can cause lipemia that interferes with optical measurements in light transmission aggregometry. A light, low-fat meal a few hours before collection and avoidance of caffeine and flavonoid-rich beverages on the testing day are commonly recommended to reduce analytical interference.